Jessica R Allegretti

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 37

Top Topics

Ulcerative Colitis

Top Venues

Inflammatory bowel diseases

Alimentary pharmacology & therapeutics

Therapeutic advances in gastroenterology

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Lindsay M Clarke, Jessica R Allegretti
The epidemiology and management of Clostridioides difficile infection-A clinical update. Alimentary pharmacology & therapeutics (2024)
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin F Wells
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in therapy (2024)
Lindsay M Clarke, Jessica R Allegretti
Review article: The epidemiology and management of Clostridioides difficile infection-A clinical update. Alimentary pharmacology & therapeutics 59 (11) (2024)
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin F Wells
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in therapy 41 (5) (2024)
Rahul S Dalal, Jessica R Allegretti
Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics? Inflammatory bowel diseases 30 (3) (2024)
Jessica R Allegretti, Liliana G Bordeianou, Oriana M Damas, Samuel Eisenstein, Ruby Greywoode, Phillip Paul Minar, Siddharth Singh, Sabrina Harmon, Eugene Lisansky, Myisha Malone-King, Nicole S Litwin, Alandra Weaver, Caren A Heller, Alan C Moss, Jeremy Adler
Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory bowel diseases 30 (Supplement_2) (2024)
Lindsay M Clarke, Jessica R Allegretti
Review article: The epidemiology and management of Clostridioides difficile infection-A clinical update. Alimentary pharmacology & therapeutics 59 (11) (2024)
Lindsay M Clarke, Jessica R Allegretti
Review article: The epidemiology and management of Clostridioides difficile infection-A clinical update. Alimentary pharmacology & therapeutics 59 (11) (2024)
Jessica R Allegretti, Liliana G Bordeianou, Oriana M Damas, Samuel Eisenstein, Ruby Greywoode, Phillip Paul Minar, Siddharth Singh, Sabrina Harmon, Eugene Lisansky, Myisha Malone-King, Nicole S Litwin, Alandra Weaver, Caren A Heller, Alan C Moss, Jeremy Adler
Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory bowel diseases 30 (Supplement_2) (2024)
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin F Wells
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in therapy 41 (5) (2024)
Rahul S Dalal, Lindsay M Clarke, Alex Carlin, Heidy Cabral, Jessica R Allegretti
Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis. Inflammatory bowel diseases (2024)
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin F Wells
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. Advances in therapy 41 (5) (2024)
Rahul S Dalal, Govind Kallumkal, Heidy J Cabral, Salam Bachour, Edward L Barnes, Jessica R Allegretti
Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study. Inflammatory bowel diseases (2023)
Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti
1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States. Inflammatory bowel diseases (2023)
Rahul S Dalal, Jessica R Allegretti
Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics? Inflammatory bowel diseases (2023)
Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti
1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure. Inflammatory bowel diseases (2023)
Zahir Kanjee, Jessica R Allegretti, Carolyn D Alonso, Risa B Burns
How Would You Manage This Patient With Clostridioides difficile Infection? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Annals of internal medicine (2023)
Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti
Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Inflammatory bowel diseases (2023)
Salam P Bachour, Rahul Dalal, Jessica R Allegretti
The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation. Therapeutic advances in gastroenterology 16 (2023)
Salam P Bachour, Rahul Dalal, Jessica R Allegretti
The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation. Therapeutic advances in gastroenterology 16 (2023)
Salam P Bachour, Rahul Dalal, Jessica R Allegretti
The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation. Therapeutic advances in gastroenterology 16 (2023)
Salam P Bachour, Rahul Dalal, Jessica R Allegretti
The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation. Therapeutic advances in gastroenterology 16 (2023)
Benjamin Harvey Mullish, Laura Martinez-Gili, Jessica R Allegretti
Editorial: the acid test-can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply. Alimentary pharmacology & therapeutics 57 (1) (2022)
Benjamin Harvey Mullish, Laura Martinez-Gili, Jessica R Allegretti
Editorial: the acid test-can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply. Alimentary pharmacology & therapeutics 57 (1) (2022)
Benjamin Harvey Mullish, Laura Martinez-Gili, Elena Chekmeneva, Gonçalo D S Correia, Matthew R Lewis, Verena Horneffer-Van Der Sluis, Lauren A Roberts, Julie A K McDonald, Alexandros Pechlivanis, Julian R F Walters, Emma L McClure, Julian R Marchesi, Jessica R Allegretti
Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection. Alimentary pharmacology & therapeutics 56 (11-12) (2022)
Rahul S Dalal, Jordan C Pruce, Jessica R Allegretti
Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases. Inflammatory bowel diseases (2022)
Rahul S Dalal, Kanwal Bains, Jenna Marcus, Emma L McClure, Jessica R Allegretti
Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series. Inflammatory bowel diseases 28 (11) (2022)
Jessica R Allegretti, Andrew Canakis, Emma McClure, Jenna Marcus, Beth-Ann Norton, Matthew J Hamilton, Rachel W Winter, Punyanganie S De Silva, Sonia Friedman, Joshua R Korzenik
Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated. Inflammatory bowel diseases 27 (12) (2022)
Brandon M Shore, Kimberly N Weaver, Jessica R Allegretti, Hans H Herfarth, Edward L Barnes
Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn's-like Disease of the Pouch. Inflammatory bowel diseases (2022)
Rahul S Dalal, Emma L McClure, Jenna Marcus, Jessica R Allegretti
Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis. Digestive diseases and sciences (2022)
Rahul S Dalal, Jennifer Mitri, Hannah Goodrick, Jessica R Allegretti
Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. Inflammatory bowel diseases 27 (10) (2022)
Benjamin Harvey Mullish, Laura Martinez-Gili, Jessica R Allegretti
Editorial: the acid test-can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply. Alimentary pharmacology & therapeutics 57 (1) (2022)
Rahul S Dalal, Jessica R Allegretti
Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause? Inflammatory bowel diseases 27 (11) (2021)
Rahul S Dalal, Sanchit Gupta, Hannah Goodrick, Jennifer Mitri, Jessica R Allegretti
Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. Inflammatory bowel diseases (2021)
Jessica R Allegretti, Cheikh Nije, Emma McClure, Walker D Redd, Danny Wong, Joyce C Zhou, Ahmad N Bazarbashi, Thomas R McCarty, Kelly E Hathorn, Lin Shen, Kunal Jajoo, Walter Wai-Yip Chan
Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019. JGH open : an open access journal of gastroenterology and hepatology 5 (5) (2021)
Rahul S Dalal, Jessica R Allegretti
Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. Inflammatory bowel diseases 27 (6) (2021)
Mina Hassan-Zahraee, Zhan Ye, Li Xi, Mary Lynn Baniecki, Xingpeng Li, Craig L Hyde, Jenny Zhang, Nancy Raha, Fridrik Karlsson, Jie Quan, Daniel Ziemek, Srividya Neelakantan, Christopher Lepsy, Jessica R Allegretti, Jacek Romatowski, Ellen J Scherl, Maria Klopocka, Silvio Danese, Deepa E Chandra, Uwe Schoenbeck, Michael S Vincent, Randy Longman, Kenneth E Hung
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Inflammatory bowel diseases (2021)